Evidence map›Paper›PMID 32855398›Full record

Observational studyNature communications2020

Multi-site clonality analysis uncovers pervasive heterogeneity across melanoma metastases.

Roy Rabbie, Naser Ansari-Pour, Oliver Cast, Doreen Lau, Francis Scott, Sarah J Welsh, Christine Parkinson, Leila Khoja, Luiza Moore, Mark Tullett and 13 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 36 citations in OpenAlex.

  1. Focused ultrasound for brain metastases.Neuro-oncology advances · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Neoantigen Targetability in Progressive Advanced Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 2 countries.

Roy Rabbie *Experimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0002-9195-5659
Naser Ansari-Pour *Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Oliver CastCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK.ORCID http://orcid.org/0000-0002-5880-7726
Doreen LauDepartment of Radiology, School of Clinical Medicine, University of Cambridge, Box 218, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0002-7623-2401
Francis ScottDepartment of Radiology, School of Clinical Medicine, University of Cambridge, Box 218, Cambridge Biomedical Campus, Cambridge, UK.
Sarah J WelshCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Christine ParkinsonCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Leila KhojaInstitute of Immunology and Immunotherapy, College of Medical and Dental Sciences, Vincent Drive, University of Birmingham, Birmingham, UK.
Luiza MooreThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0001-5315-516X
Mark TullettSt Richard's Hospital, Spitalfield Lane, Chichester, UK.
Kim WongExperimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0002-0984-1477
Ingrid FerreiraExperimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0002-4321-5250
Julia M Martínez GómezDepartment of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland.
Mitchell LevesqueDepartment of Dermatology, University of Zurich, University of Zurich Hospital, Gloriastrasse 31, CH-8091, Zurich, Switzerland.
Ferdia A GallagherDepartment of Radiology, School of Clinical Medicine, University of Cambridge, Box 218, Cambridge Biomedical Campus, Cambridge, UK.ORCID http://orcid.org/0000-0003-4784-5230
Alejandro Jiménez-SánchezCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK.
Laura RivaExperimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Martin L MillerCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK.ORCID http://orcid.org/0000-0003-3161-8690
Kieren AllinsonDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Peter J CampbellThe Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK.ORCID http://orcid.org/0000-0002-3921-0510
Pippa CorrieCambridge Cancer Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
David C WedgeBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK. david.wedge@manchester.ac.uk.ORCID http://orcid.org/0000-0002-7572-3196
David J AdamsExperimental Cancer Genetics, The Wellcome Sanger Institute, Hinxton, Cambridgeshire, UK. da1@sanger.ac.uk.ORCID http://orcid.org/0000-0001-9490-0306
Cambridge University Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GBWellcome Sanger Institute · GBUniversity of Zurich · CHOpen Data Institute · GBSt Richard's Hospital · GBUniversity of Birmingham · GBUniversity of Manchester · GB

Funding

Cancer Research UK 16628Cancer Research UK 21141Cancer Research UK 21717Cancer Research UK 27150Department of HealthMedical Research Council MR/T024097/1Wellcome Trust
6 · The paper itself

Abstract

Metastatic melanoma carries a poor prognosis despite modern systemic therapies. Understanding the evolution of the disease could help inform patient management. Through whole-genome sequencing of 13 melanoma metastases sampled at autopsy from a treatment naïve patient and by leveraging the analytical power of multi-sample analyses, we reveal evidence of diversification among metastatic lineages. UV-induced mutations dominate the trunk, whereas APOBEC-associated mutations are found in the branches of the evolutionary tree. Multi-sample analyses from a further seven patients confirmed that lineage diversification was pervasive, representing an important mode of melanoma dissemination. Our analyses demonstrate that joint analysis of cancer cell fraction estimates across multiple metastases can uncover previously unrecognised levels of tumour heterogeneity and highlight the limitations of inferring heterogeneity from a single biopsy.

Indexed as

Clonal EvolutionGenetic HeterogeneityAgedBiopsyDNA Mutational AnalysisHumansMaleMelanomaProspective StudiesSkinSkin NeoplasmsWhole Genome Sequencing

Identifiers

PMID32855398
PMCPMC7453196
OpenAlexW3080337050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.